Position in ASND
as of Mar 31, 2026
· filed Apr 29, 2026
Position Value
$931,388
+$458,635 QoQ
Shares Held
4,072
+83.7% QoQ
Ownership
0.006%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#165
of 265 holders
Holding Since
Dec 2024
5 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in ASND Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Brooklyn Investment Group holds $23,138,608 across 42 Biotechnology names. ASND ranks #7 (4.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
6,245 | $2,788,642 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,889 | $1,459,516 | |
| 3 | ROIV |
Roivant Sciences Ltd.
|
50,312 | $1,393,642 | |
| 4 | ARGX |
Argenx SE
|
1,697 | $1,239,234 | |
| 5 | MRNA |
Moderna, Inc.
|
23,110 | $1,173,988 | |
| 6 | GMAB |
Genmab A/S
|
35,823 | $961,131 | |
| 7 | ASND |
Ascendis Pharma A/S
This page
|
4,072 | $931,388 | |
| 8 | RVMD |
Revolution Medicines, Inc.
|
8,994 | $874,666 |
All Filings in ASND
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $931,388 | 4,072 | Shares | Defined | 2026-04-29 | |
| 2025-12-31 | $472,753 | 2,217 | Shares | Defined | 2026-02-12 | |
| 2025-06-30 | $134,800 | 781 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $55,330 | 355 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 | $11,288 | 82 | Shares | Defined | 2025-01-15 | |
| No filing history on record for this holder in this stock. | ||||||